Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up

MT Newswires Live

Apr 05, 2025

Sonnet BioTherapeutics (SONN) shares were up 3% Friday after the company said that safety results from a phase 1b/2a trial of SON-1010 plus atezolizumab in patients with advanced solid tumors or platinum-resistant ovarian cancer were "positive."

The study aimed to test the safety, tolerability, and effectiveness of increasing doses of SON-1010 with atezolizumab. The main goal was to find the maximum tolerated dose when combined with the immune checkpoint inhibitor. A total of 19 patients were treated, and one patient with platinum-resistant ovarian cancer showed a partial response at the highest dose, the company said.

Based on positive feedback from the Safety Review Committee, the biotechnology company also said that the study will move to an expansion phase, which will assess the preliminary effects of the combination at the highest dose, leading to a phase 2a comparison with the standard treatment.

Price: 1.31, Change: +0.04, Percent Change: +3.07

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2525386417"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2525386417\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2525386417?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-05 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525386417","market":"sh","top_or_hot":-1,"title":"Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up","media":"MT Newswires Live","content":"<html><body><p> Sonnet BioTherapeutics (SONN) shares were up 3% Friday after the company said that safety results from a phase 1b/2a trial of SON-1010 plus atezolizumab in patients with advanced solid tumors or platinum-resistant ovarian cancer were \"positive.\"</p><p>The study aimed to test the safety, tolerability, and effectiveness of increasing doses of SON-1010 with atezolizumab. The main goal was to find the maximum tolerated dose when combined with the immune checkpoint inhibitor. A total of 19 patients were treated, and one patient with platinum-resistant ovarian cancer showed a partial response at the highest dose, the company said.</p><p>Based on positive feedback from the Safety Review Committee, the biotechnology company also said that the study will move to an expansion phase, which will assess the preliminary effects of the combination at the highest dose, leading to a phase 2a comparison with the standard treatment.</p><p>Price: 1.31, Change: +0.04, Percent Change: +3.07</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-05 00:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Sonnet BioTherapeutics (SONN) shares were up 3% Friday after the company said that safety results from a phase 1b/2a trial of SON-1010 plus atezolizumab in patients with advanced solid tumors or platinum-resistant ovarian cancer were \"positive.\"</p><p>The study aimed to test the safety, tolerability, and effectiveness of increasing doses of SON-1010 with atezolizumab. The main goal was to find the maximum tolerated dose when combined with the immune checkpoint inhibitor. A total of 19 patients were treated, and one patient with platinum-resistant ovarian cancer showed a partial response at the highest dose, the company said.</p><p>Based on positive feedback from the Safety Review Committee, the biotechnology company also said that the study will move to an expansion phase, which will assess the preliminary effects of the combination at the highest dose, leading to a phase 2a comparison with the standard treatment.</p><p>Price: 1.31, Change: +0.04, Percent Change: +3.07</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2525386417","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525386417","pubTimestamp":1743784567,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sonnet BioTherapeutics  shares were up 3% Friday after the company said that safety results from a phase 1b/2a trial of SON-1010 plus atezolizumab in patients with advanced solid tumors or platinum-resistant ovarian cancer were \"positive.\"The study aimed to test the safety, tolerability, and effectiveness of increasing doses of SON-1010 with atezolizumab. The main goal was to find the maximum tolerated dose when combined with the immune checkpoint inhibitor. A total of 19 patients were treated, and one patient with platinum-resistant ovarian cancer showed a partial response at the highest dose, the company said.Based on positive feedback from the Safety Review Committee, the biotechnology company also said that the study will move to an expansion phase, which will assess the preliminary effects of the combination at the highest dose, leading to a phase 2a comparison with the standard treatment.Price: 1.31, Change: +0.04, Percent Change: +3.07","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SONN":"Sonnet BioTherapeutics Holdings, Inc."},"translate_title":"Sonnet BioTherapeutics表示卵巢癌药物在1b/2a期试验中显示出“积极”的安全性数据；股票上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SONN":0.9},"content_text":"Sonnet BioTherapeutics (SONN) shares were up 3% Friday after the company said that safety results from a phase 1b/2a trial of SON-1010 plus atezolizumab in patients with advanced solid tumors or platinum-resistant ovarian cancer were \"positive.\"The study aimed to test the safety, tolerability, and effectiveness of increasing doses of SON-1010 with atezolizumab. The main goal was to find the maximum tolerated dose when combined with the immune checkpoint inhibitor. A total of 19 patients were treated, and one patient with platinum-resistant ovarian cancer showed a partial response at the highest dose, the company said.Based on positive feedback from the Safety Review Committee, the biotechnology company also said that the study will move to an expansion phase, which will assess the preliminary effects of the combination at the highest dose, leading to a phase 2a comparison with the standard treatment.Price: 1.31, Change: +0.04, Percent Change: +3.07","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}